NCT03559309View on ClinicalTrials.gov

Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia

PHASE4TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

February 5, 2020

Study Completion Date

February 5, 2020

Conditions
AtherosclerosisHypercholesterolemiaPost Prandial LipemiaCardiovascular Diseases
Interventions
DIAGNOSTIC_TEST

Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing

Patients treated with Alirocumab in the clinical routine will have additional diagnostic tests as stated above. The clinical trial will be conducted as an open label, single arm study. The diagnostic tests will be done at baseline (BL) and after 10 weeks of treatment (W10) with Alirocumab.

Trial Locations (1)

A-8036

Medical University of Graz, Graz

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

numares AG

UNKNOWN

collaborator

Sanofi

INDUSTRY

lead

Medical University of Graz

OTHER

NCT03559309 - Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia | Biotech Hunter | Biotech Hunter